Researchers have discovered that a person's "bioenergetic age," reflecting how efficiently cells produce energy, strongly ...

Scientists have discovered that how well a person’s cells generate energy—what they call “bioenergetic age”—could be a strong ...

Spatial transcriptomics on human brains parsed microglial reactions to amyloid immunotherapy. Both a vaccine and a therapeutic antibody summoned these cells to plaques. Responders expressed TREM2, ...

Overall, lecanemab’s ARIA incidence profile was within expectations based on the phase 2b results. Both Eisai and Biogen co-commercialise and co-promote lecanemab, while Eisai has final decision ...

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer's disease therapy lecanemab, which is now fully filed with the FDA.

While researchers continue to work on a full cure for Alzheimer's disease, they're finding treatments that can help manage ...

A person's "bioenergetic age"—or how youthfully their cells generate energy—might be a key indicator of whether they're at ...

Chicago area scientists have identified the genes that drive the process of Alzheimer’s disease and are working to make the drug Lecanemab even better by identifying which genes are active ...

Uppsala University announced today that BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) two founders, Lars Lannfelt and Pär Gellerfors, ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...